Ashley Velez-Delgado

Ashley Velez-Delgado

Auto-generated profile, based on publicly available information

Ashley Velez-Delgado

University of Michigan 8 Department of Cell and Developmental Biology Ann Arbor, Michigan

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2022 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
WDWenting Du
Wenting Du
RMRosa E. Menjivar
Rosa E. Menjivar
KDKatelyn L. Donahue
Katelyn L. Donahue
PKPadma Kadiyala
Padma Kadiyala
AVAshley Velez-Delgado
Ashley Velez-Delgado
MMMarina Pasca di Magliano
Marina Pasca di Magliano
Pancreatic ductal adenocarcinoma (PDA) is associated with activation of WNT signaling. Whether this signaling pathway regulates the tumor microenvironment has remained unexplored. Through single-cell RNA sequencing of human pancreatic cancer, we discovered that tumor-infiltrating CD4+ T cells express TCF7, encoding for the transcription factor TCF1. We conditionally inactivated Tcf7 in CD4 expressing T cells in a mouse model of pancreatic cancer and observed changes in the tumor immune microenvironment, including more CD8+ T cells and fewer regulatory T cells, but also compensatory upregulation of PD-L1. We then used a clinically available inhibitor of Porcupine, a key component of WNT signaling, and observed similar reprogramming of the immune response. WNT signaling inhibition has limited therapeutic window due to toxicity, and PD-L1 blockade has been ineffective in PDA. Here, we show that combination targeting reduces pancreatic cancer growth in an experimental model and might benefit the treatment of pancreatic cancer.

3 July 2024 in Cancer Discovery
Verified
Journal Article
Open access
KDKatelyn L. Donahue
Katelyn L. Donahue
HWHannah R. Watkoske
Hannah R. Watkoske
PKPadma Kadiyala
Padma Kadiyala
WDWenting Du
Wenting Du
KBKristee Brown
Kristee Brown
MMMarina Pasca di Magliano
Marina Pasca di Magliano
Pancreatic cancer is characterized by an extensive fibroinflammatory microenvironment. During carcinogenesis, normal stromal cells are converted to cytokine-high cancer-associated fibroblasts (CAF). The mechanisms underlying this conversion, including the regulation and function of fibroblast-derived cytokines, are poorly understood. Thus, efforts to therapeutically target CAFs have so far failed. Herein, we show that signals from epithelial cells expressing oncogenic KRAS—a hallmark pancreatic cancer mutation—activate fibroblast autocrine signaling, which drives the expression of the cytokine IL33. Stromal IL33 expression remains high and dependent on epithelial KRAS throughout carcinogenesis; in turn, environmental stress induces interleukin-33 (IL33) secretion. Using compartment-specific IL33 knockout mice, we observed that lack of stromal IL33 leads to profound reprogramming of multiple components of the pancreatic tumor microenvironment, including CAFs, myeloid cells, and lymphocytes. Notably, loss of stromal IL33 leads to an increase in CD8+ T-cell infiltration and activation and, ultimately, reduced tumor growth. Significance: This study provides new insights into the mechanisms underlying the programming of CAFs and shows that during this process, expression of the cytokine IL33 is induced. CAF-derived IL33 has pleiotropic effects on the tumor microenvironment, supporting its potential as a therapeutic target.

24 June 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
RMRosa E. Menjivar
Rosa E. Menjivar
ZNZeribe Chike Nwosu
Zeribe Chike Nwosu
WDWenting Du
Wenting Du
KDKatelyn L. Donahue
Katelyn L. Donahue
CECarlos Espinoza
Carlos Espinoza
MMMarina Pasca di Magliano
Marina Pasca di Magliano
An extensive fibroinflammatory stroma rich in macrophages is a hallmark of pancreatic cancer. In this disease, it is well appreciated that macrophages are immunosuppressive and contribute to the poor response to immunotherapy; however, the mechanisms of immune suppression are complex and not fully understood. Immunosuppressive macrophages are classically defined by expression of the enzyme Arginase 1 (Arg1), which we demonstrated is potently expressed in pancreatic tumor associated macrophages from both human patients and mouse models. While routinely used as a polarization marker, Arg1 also catabolizes arginine, an amino acid required for T cell activation and proliferation. To investigate this metabolic function, we used a genetic and a pharmacologic approach to target Arg1 in pancreatic cancer. Genetic inactivation of Arg1 in macrophages, using a dual recombinase genetically engineered mouse model of pancreatic cancer, delayed formation of invasive disease, while increasing CD8 + T cell infiltration. Treatment of established tumors with the arginase inhibitor CB-1158 exhibited further increased CD8 + T cell infiltration, beyond that seen with the macrophage-specific knockout, and sensitized the tumors to anti-PD1 immune checkpoint blockade. Thus, our data demonstrate that Arg1 is more than simply a marker of macrophage function. Rather, Arg1 is also a driver of immune suppression and represents a promising immunotherapeutic target for pancreatic cancer.


8 July 2026 in Cancer Immunology Research
Verified
Journal Article
Open access
YZYaqing Zhang
Yaqing Zhang
PKPadma Kadiyala
Padma Kadiyala
WYWei Yan
Wei Yan
KBKristee Brown
Kristee Brown
FAFaith R. Avritt
Faith R. Avritt
MMMarina Pasca di Magliano
Marina Pasca di Magliano
A hallmark of pancreatic cancer is an extensive fibroinflammatory stroma. Myeloid cells, including abundant macrophages, are a prevalent cellular component of the pancreatic cancer microenvironment and a key driver of immunosuppression. Identifying mechanisms of myeloid cell–driven immunosuppression is thus key to developing therapeutic approaches. Harnessing single-cell RNA sequencing data from human and murine tumors, we determined that tumor-infiltrating myeloid cells (including macrophages and granulocytes) have elevated expression of C-C motif chemokine receptor 1 (CCR1). To determine the functional role of CCR1, we generated oncogenic KRAS-based genetically engineered mouse models of pancreatic cancer, with or without the addition of a mutant form of the tumor suppressor Trp53 (KC and KPC, respectively), lacking CCR1 expression. CCR1 inactivation did not affect the formation of early lesions but delayed progression to cancer and resulted in prolonged survival. In these mice, macrophages lacking CCR1 had reduced expression of the immunosuppressive marker arginase 1. Loss of CCR1 also profoundly shifted the prevalent fibroblast population, inducing a pancreatic stellate cell–like phenotype. In two independent syngeneic orthotopic models, ablation or pharmacologic inhibition of CCR1 reduced tumor growth and increased CD8+ T-cell cytotoxic activity, sensitizing tumors to immunotherapy. Our data show that CCR1-expressing myeloid cells promote pancreatic cancer growth through modulation of the immune microenvironment and fibroblasts, indicating that CCR1 might be a suitable target for combination therapy.

17 June 2026
Verified
Other
Open access
PDF file
KDKatelyn L. Donahue
Katelyn L. Donahue
HWHannah R. Watkoske
Hannah R. Watkoske
PKPadma Kadiyala
Padma Kadiyala
WDWenting Du
Wenting Du
KBKristee Brown
Kristee Brown
MMMarina Pasca di Magliano
Marina Pasca di Magliano
Figure S6: Expression of fibroblast IL-33 is extrinsically induced by epithelial KrasG12D and requires JAK1/2-STAT3 activation throughout tumorigenesis.